Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- EYPT
- Price
- 14.91
- Stock movement up
- +1.97 (15.22%)
- Company name
- Eyepoint Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.23B
- Ent value
- 1.21B
- Price/Sales
- 29.15
- Price/Book
- 6.17
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -15.65%
- 1 year return (CAGR)
- 136.29%
- 3 year return (CAGR)
- 52.91%
- 5 year return (CAGR)
- 2.58%
- 10 year return (CAGR)
- -7.86%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
EYPT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 29.15 |
| Price to Book | 6.17 |
| EV to Sales | 28.61 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 82.79M |
| EPS (TTM) | -2.93 |
| FCF per share (TTM) | -3.04 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 42.34M |
| Gross profit (TTM) | 39.83M |
| Operating income (TTM) | -218.33M |
| Net income (TTM) | -205.75M |
| EPS (TTM) | -2.93 |
| EPS (1y forward) | -2.82 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 94.08% |
| Operating margin (TTM) | -515.65% |
| Profit margin (TTM) | -485.95% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 74.58M |
| Net receivables | 1.04M |
| Total current assets | 216.11M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 29.52M |
| Total assets | 251.69M |
| Accounts payable | 28.02M |
| Short/Current long term debt | 21.30M |
| Total current liabilities | 30.09M |
| Total liabilities | 51.51M |
| Shareholder's equity | 200.18M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -210.91M |
| Capital expenditures (TTM) | 2.68M |
| Free cash flow (TTM) | -213.59M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -102.78% |
| Return on Assets | -81.75% |
| Return on Invested Capital | -102.78% |
| Cash Return on Invested Capital | -106.70% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 12.40 |
| Daily high | 15.69 |
| Daily low | 12.34 |
| Daily Volume | 8.72M |
| All-time high | 382.00 |
| 1y analyst estimate | 36.08 |
| Beta | 1.79 |
| EPS (TTM) | -2.93 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 5 Mar 2026 |
Downside potential
Loading...
Downside potential data
| EYPT | S&P500 | |
| Current price drop from All-time high | -96.10% | -1.82% |
| Highest price drop | -99.40% | -56.47% |
| Date of highest drop | 24 Mar 2023 | 9 Mar 2009 |
| Avg drop from high | -89.76% | -10.84% |
| Avg time to new high | 2628 days | 12 days |
| Max time to new high | 5256 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.23B
Marketcap category
Small-cap
Description
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Employees
165
Website
Investor relations
-
SEC filings
CEO
Nancy Sue Lurker
Country
USA
City
Watertown
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page